Bo Shen

7PUBLICATIONS
46CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 19, 2026
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Bo Shen, Chun Wang, Liqin Zhang

|Dec 26, 2024
Prognostic Significance of <i>Methyl-CpG Binding Domain4</i> Polymorphism rs140693 and Clinical Characteristics in Chinese Lung Cancer Patients.

Zhengxing Li, Yuewen Hu, Chang Xu

|Sep 04, 2024
FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis.

Dan Zou, Bowen Hu, Sitong Feng

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

|Nov 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Dingzhi Huang, Gen Lin, Qian Chu

|Nov 28, 2022
A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

Xing Huang, Zhichao Lu, Min He

Pageof 2

Frequent Collaborators

2 joint publications

Chengbo Han

2 joint publications

Yong He

2 joint publications

Jianchun Duan

2 joint publications

Meijuan Huang